Weekly Digest - October 2024

Weekly Digest - October 2024

30 Sep 2024: Alphamab Oncology and CSPC enter licensing agreement for Anti-HER2 bispecific ADC JSKN003

  • Alphamab Oncology announced a licensing agreement for the anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology, a subsidiary of CSPC Pharmaceutical Group
  • Under the agreement, JMT-Bio gains exclusive rights to develop, sell, and commercialize JSKN003 for tumor-related indications in mainland China, excluding Hong Kong, Macau, and Taiwan
  • Alphamab will receive an upfront payment of RMB 400 million, with potential milestone payments totaling up to RMB 3.08 billion, including royalties on net sales
  • JSKN003 was developed using Alphamab’s proprietary conjugation platform, showing better serum stability and efficacy in clinical trials involving heavily pretreated patients with advanced solid tumors

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home